Drugs / alagebrium
alagebrium
also known as
ALT-711 · alagebrium chloride · Alagebrium cation · Alagebrium ion · Chlorure d'alagebrium · Cloruro de alagebrio
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 210 trials | ||||||
| Phase 2 | NCT00739687 | Aug 2008 → Aug 2009 | heart failure | Synvista Therapeutics, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01014572 | Jul 2008 → Jun 2012 | cardiac ventricle disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00662116 | Mar 2008 → Oct 2009 | diastolic heart failure | Synvista Therapeutics, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01913301 | Dec 2007 → May 2009 | diastolic heart failure | Cardiovascular Clinical Sciences Inc | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00302250 | Feb → Dec 2006 | cardiovascular disorder | Synvista Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00089713 | Mar 2004 → ? | hypertensive disorder | Synvista Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00277875 | Feb → Dec 2004 | cardiovascular disorder | Synvista Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00043836 | Jul 2002 → Feb 2003 | congestive heart failure, pulmonary edema | Synvista Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00045981 | Oct 2001 → May 2003 | hypertensive disorder | Synvista Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00045994 | Aug 2001 → Jan 2002 | hypertensive disorder | Synvista Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01417663 | Nov 2008 → Jun 2011 | cardiovascular disorder | Radboud University Medical Center | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00557518 Comparator | Nov 2007 → Sep 2009 | diabetic kidney disease, type 1 diabetes mellitus | Synvista Therapeutics, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00516646 Comparator | Aug 2007 → Aug 2009 | heart failure | Synvista Therapeutics, Inc | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alagebrium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00557518 ↗ |
| Known as | Alagebrium cation | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111081 ↗ |
| Known as | alagebrium chloride | “alagebrium chloride (ALT-711)” NCT00089713 ↗ |
| Known as | Alagebrium ion | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111081 ↗ |
| Known as | ALT-711 | “The purpose of this study is to determine whether an investigational drug (Alagebrium (generic: ALT-711), a type of medication referred to as an advanced glycaton end-product...” NCT01014572 ↗9“ALT-711 (alagebrium chloride)” NCT00302250 ↗ “alagebrium chloride (ALT-711)” NCT00089713 ↗ “ALT-711 (alagebrium chloride)” NCT00277875 ↗ |
| Known as | Chlorure d'alagebrium | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111081 ↗ |
| Known as | Cloruro de alagebrio | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111081 ↗ |
| Modality | Other / unclassified | “The AGE-crosslink breaker Alagebrium (ALT-711) improved cardiac function and symptoms in experimental and small human heart failure studies.” NCT00516646 ↗ |
| Modality | Small molecule | — CHEMBL2111081 ↗ |
| Route | Oral | “with oral ALT-711” NCT00045981 ↗ |